Characterization of the histone deacetylase inhibition effects applied to a recombinant enzyme used in the Gaucher disease treatment

Vol. 1, 2019. - 116503
Pôster
Favorite this paper
How to cite this paper?
Abstract

Enzyme replacement therapy using recombinant enzyme was the first therapeutic option for Gaucher disease approved by FDA.1 This study evaluated how the histone deacetylase inhibitor SAHA interferes in the β-glycosylceramidase (GBA) production. First, the dose of SAHA inhibitor was established. Then the cell lines were treated with SAHA for 48 hour and the GBA enzymatic activity was measured by the fluorimetric enzyme assy.2 Following the treatment, the transgenic cell line showed a 2.04-fold increase in intracellular GBA (p<0.0001) and a 1.9-fold inhibition of secreted GBA (p<0,0001). For the virgin cell line, we observed an increase in intracellular enzyme about 3.8-fold (p=0.0001) and an increase in the level of secreted GBA enzyme, approximately 2.06-fold (p=0.006). Spearman correlation showed a significant positive correlation between the levels of secreted and intracellular GBA (rho=0.709 and p=0.027). These data show that SAHA treatment significantly increased the GBA production in both cell lines.

Institutions
  • 1 Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto / Universidade de São Paulo
  • 2 Faculdade de Medicina de Ribeirão Preto / Universidade de São Paulo
Track
  • Biotechnology
Keywords
Gaucher Disease
epigenetic
β-glycosylceramidase